| Project item | Indications | Research phase | Cooperation demands |
| BDA202203 | B7H3+ and PD-L1+/low cancer | CMC development | License-out or co-development |
| BDA202206 | Broad cancer | PCC | License-out or co-development the global right |
| BEX202203 | Solid tumor | IND | License-out or co-development |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBS-K040 | Human | Human B7-H3(4Ig)-coupled Magnetic Beads | |||
| B73-C52Ha | Cynomolgus | Cynomolgus B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-H82F5 | Human | Biotinylated Human B7-H3 / CD276 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| B73-H82E6 | Human | Biotinylated Human B7-H3 / CD276 Protein, Avitag™,His Tag |  |
|
|
| B73-M52H4 | Mouse | Mouse B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-M5255 | Mouse | Mouse B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |
|
|
| B73-H52E2 | Human | Human B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-H5253 | Human | Human B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |
|
|
Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 53-75 kDa verified by SEC-MALS.
Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Monoclonal antibody 8H9 I-124 | 124I-8H9; 124I-8H9-(B7-H3) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Glioma | Details |
| Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
| CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Shenzhen University General Hospital | Details | ||
| EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Second Affiliated Hospital Of Guangzhou Medical University | Details | ||
| DS-5573 | DS-5573; DS-5573a | Daiichi Sankyo Co Ltd | Details | ||
| B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details | |||
| B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Sarcoma, Synovial; Melanoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
| 4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Neoplasms, Germ Cell and Embryonal; Melanoma; Choroid Plexus Neoplasms; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Solid tumours; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Desmoplastic Small Round Cell Tumor; Rhabdoid Tumor; Carcinoma; Hepatoblastoma; Rhabdomyosarcoma; Ependymoma; Teratoma; Medulloblastoma | Details |
| B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
| Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
| Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
| TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
| Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Sarcoma, Ewing; Osteosarcoma; Neuroblastoma; Urethral Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Abdominal Neoplasms; Desmoplastic Small Round Cell Tumor; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma; Ovarian Neoplasms; Solid tumours | Details |
| TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
| Vobramitamab duocarmazine | MGC-018 | Phase 3 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Pancreatic Ductal; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
